The content on this site is intended for healthcare professionals only
Dr Noemi Puig speaks to ecancer online at the MyKE20 meeting about the new techniques to detect minimal residual disease (MRD) in the bone marrow.
She outlines some of the barriers which face detecting this MRD, and why mass spectrometry was chosen to be studied for its effectiveness.
Dr Puig outlines this trial design, and how successful the mass spectrometry was in detecting MRD.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
Choosing Wisely in radiology Tanzania
Moving to the future: Artificial intelligence in surgery
